Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2006 1
2008 3
2009 3
2010 4
2011 2
2012 5
2013 5
2014 5
2015 5
2016 5
2017 5
2018 4
2019 7
2020 12
2021 17
2022 17
2023 8
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Results by year

Filters applied: . Clear all
Page 1
The human tumor microbiome is composed of tumor type-specific intracellular bacteria.
Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT, Rotter-Maskowitz A, Weiser R, Mallel G, Gigi E, Meltser A, Douglas GM, Kamer I, Gopalakrishnan V, Dadosh T, Levin-Zaidman S, Avnet S, Atlan T, Cooper ZA, Arora R, Cogdill AP, Khan MAW, Ologun G, Bussi Y, Weinberger A, Lotan-Pompan M, Golani O, Perry G, Rokah M, Bahar-Shany K, Rozeman EA, Blank CU, Ronai A, Shaoul R, Amit A, Dorfman T, Kremer R, Cohen ZR, Harnof S, Siegal T, Yehuda-Shnaidman E, Gal-Yam EN, Shapira H, Baldini N, Langille MGI, Ben-Nun A, Kaufman B, Nissan A, Golan T, Dadiani M, Levanon K, Bar J, Yust-Katz S, Barshack I, Peeper DS, Raz DJ, Segal E, Wargo JA, Sandbank J, Shental N, Straussman R. Nejman D, et al. Among authors: bar j. Science. 2020 May 29;368(6494):973-980. doi: 10.1126/science.aay9189. Science. 2020. PMID: 32467386 Free PMC article.
Interferon-stimulated neutrophils as a predictor of immunotherapy response.
Benguigui M, Cooper TJ, Kalkar P, Schif-Zuck S, Halaban R, Bacchiocchi A, Kamer I, Deo A, Manobla B, Menachem R, Haj-Shomaly J, Vorontsova A, Raviv Z, Buxbaum C, Christopoulos P, Bar J, Lotem M, Sznol M, Ariel A, Shen-Orr SS, Shaked Y. Benguigui M, et al. Among authors: bar j. Cancer Cell. 2024 Feb 12;42(2):253-265.e12. doi: 10.1016/j.ccell.2023.12.005. Epub 2024 Jan 4. Cancer Cell. 2024. PMID: 38181798 Free PMC article.
The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response.
Cohen M, Giladi A, Barboy O, Hamon P, Li B, Zada M, Gurevich-Shapiro A, Beccaria CG, David E, Maier BB, Buckup M, Kamer I, Deczkowska A, Le Berichel J, Bar J, Iannacone M, Tanay A, Merad M, Amit I. Cohen M, et al. Among authors: bar j. Nat Cancer. 2022 Mar;3(3):303-317. doi: 10.1038/s43018-022-00338-5. Epub 2022 Mar 3. Nat Cancer. 2022. PMID: 35241835
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B. Girard N, et al. Among authors: bar j. J Thorac Oncol. 2023 Feb;18(2):181-193. doi: 10.1016/j.jtho.2022.10.003. Epub 2022 Oct 25. J Thorac Oncol. 2023. PMID: 36307040 Free article.
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC.
Javitt A, Shmueli MD, Kramer MP, Kolodziejczyk AA, Cohen IJ, Radomir L, Sheban D, Kamer I, Litchfield K, Bab-Dinitz E, Zadok O, Neiens V, Ulman A, Wolf-Levy H, Eisenberg-Lerner A, Kacen A, Alon M, Rêgo AT, Stacher-Priehse E, Lindner M, Koch I, Bar J, Swanton C, Samuels Y, Levin Y, da Fonseca PCA, Elinav E, Friedman N, Meiners S, Merbl Y. Javitt A, et al. Among authors: bar j. Nat Cancer. 2023 May;4(5):629-647. doi: 10.1038/s43018-023-00557-4. Epub 2023 May 22. Nat Cancer. 2023. PMID: 37217651
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN).
Bar J, Peled N, Schokrpur S, Wolner M, Rotem O, Girard N, Aboubakar Nana F, Derijcke S, Kian W, Patel S, Gantz-Sorotsky H, Zer A, Moskovitz M, Metro G, Rottenberg Y, Calles A, Hochmair M, Cuppens K, Decoster L, Reck M, Limon D, Rodriguez E, Astaras C, Bettini A, Häfliger S, Addeo A. Bar J, et al. J Thorac Oncol. 2023 Feb;18(2):169-180. doi: 10.1016/j.jtho.2022.10.004. Epub 2022 Oct 25. J Thorac Oncol. 2023. PMID: 36307041 Free article.
Involvement of stromal p53 in tumor-stroma interactions.
Bar J, Moskovits N, Oren M. Bar J, et al. Semin Cell Dev Biol. 2010 Feb;21(1):47-54. doi: 10.1016/j.semcdb.2009.11.006. Epub 2009 Nov 13. Semin Cell Dev Biol. 2010. PMID: 19914385 Free PMC article. Review.
Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancer.
Daher S, Zer A, Tschernichovsky R, Yacobi R, Barshack I, Tsabari S, Rottenberg Y, Zick A, Gottfried T, Lobachov A, Marom EM, Urban D, Saad A, Gantz-Sorotsky H, Onn A, Bar J. Daher S, et al. Among authors: bar j. Lung Cancer. 2023 Apr;178:229-236. doi: 10.1016/j.lungcan.2023.02.023. Epub 2023 Mar 2. Lung Cancer. 2023. PMID: 36898331 Free article.
Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy.
Bar J, Leibowitz R, Reinmuth N, Ammendola A, Jacob E, Moskovitz M, Levy-Barda A, Lotem M, Katsenelson R, Agbarya A, Abu-Amna M, Gottfried M, Harkovsky T, Wolf I, Tepper E, Loewenthal G, Yellin B, Brody Y, Dahan N, Yanko M, Lahav C, Harel M, Raveh Shoval S, Elon Y, Sela I, Dicker AP, Shaked Y. Bar J, et al. Front Immunol. 2024 Feb 29;15:1364473. doi: 10.3389/fimmu.2024.1364473. eCollection 2024. Front Immunol. 2024. PMID: 38487531 Free PMC article.
100 results